Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels : Frequent utilization in the field of oncology

enthalten in: Clinical pharmacology and therapeutics | 2017

von Yoshida, K. | Budha, N. | Jin, J.

Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncology

enthalten in: Clinical pharmacology & therapeutics | 2017

von Yoshida, K. | Budha, N. | Jin, J.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

enthalten in: Clinical cancer research | 2016

von Tolcher, A. | Bendell, J. | Papadopoulos, K. | +12

A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors

enthalten in: Cancer discovery | 2016

von Saura, C. | Roda, D. | Rosello, S. | +18

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations

enthalten in: CPT: pharmacometrics & systems pharmacology | 2014

von Gadkar, K. | Budha, N. | Baruch, A. | +3

Response to “Drug Interactions Produced by Proton Pump Inhibitors: Not Simply a pH Effect”

enthalten in: Clinical pharmacology & therapeutics | 2013

von Budha, N. | Benet, L. | Ware, J.

Response to "Drug interactions produced by proton pump inhibitors : not simply a pH effect"

enthalten in: Clinical pharmacology and therapeutics | 2013

von Budha, N. | Benet, L. | Ware, J.

611 Assessment of CYP3A Inhibition, Food Effect, and Glucose/insulin Changes with Prednisone Co-administration in a Phase 1 Trial of the Oral, ATP-competitive Akt Inhibitor GDC-0068

enthalten in: The European journal of cancer / A | 2012

von Musib, L. | Budha, N. | Funke, R. | +7

Drug absorption interactions between oral targeted anticancer agents and PPIs : is pH-dependent solubility the Achilles heel of targeted therapy?

enthalten in: Clinical pharmacology and therapeutics | 2012

von Budha, N. | Frymoyer, A. | Smelick, G. | +6

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

enthalten in: Clinical pharmacology & therapeutics | 2012

von Budha, N. | Frymoyer, A. | Smelick, G. | +6